ASTX-6660 is under clinical development by Astex Pharmaceuticals and currently in Phase II for Diffuse Large B-Cell Lymphoma. According to GlobalData, Phase II drugs for Diffuse Large B-Cell Lymphoma have a 42% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ASTX-6660’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ASTX-660 (AT-IAP) is under development for the treatment of solid tumors, lymphomas such as diffuse large B-cell lymphoma, triple negative breast cancer (TNBC), glioblastoma, recurrent head, and neck squamous cell carcinoma, laryngeal cancer, oropharyngeal cancer, hypopharyngeal cancer, nasopharyngeal cancer, breast cancer, cervical carcinoma, relapsed or refractory peripheral T-cell lymphoma (PTCL), relapsed or refractory cutaneous T-cell lymphoma (CTCL), relapsed or refractory adult T-cell leukemia/lymphoma (ATLL), angioimmunoblastic T-cell lymphoma, anaplastic large-cell lymphoma (ALCL) and melanoma. The drug candidate is administered through the oral route. It is a dual antagonist of XIAP and cIAP1. The drug is developed based on Pyramid technology. It was also under development for the treatment of leukemia, relapsed and refractory (R/R) acute myeloid leukemia.
Astex Pharmaceuticals overview
Astex Pharmaceuticals, a subsidiary of Otsuka Holdings Co Ltd, is a drug discovery and development company with a focus on cancer and central nervous system (CNS) diseases. The company’s proprietary fragment-based drug discovery platform, Pyramid delivers high-quality and customized drug leads across a variety of therapeutic targets and disease areas. Its pipeline product and programs include DNMT inhibitor, Oral DNMT inhibitor, dual IAP antagonist, oral murine double minute 2 (MDM2) antagonist and extracellular signal-related protein kinases inhibitor. Astex Pharmaceuticals is also advancing several of its compounds into clinical trials in collaboration with Novartis, AstraZeneca, GSK, and Janssen. The company operates as a subsidiary of Otsuka Pharmaceutical Co Ltd. Astex Pharmaceuticals is headquartered in Pleasanton, California, the US.
For a complete picture of ASTX-6660’s drug-specific PTSR and LoA scores, buy the report here.